哈尔滨三联药业股份有限公司 舆情管理制度 第一条 为提高哈尔滨三联药业股份有限公司（以下简称"公司"）应对各类 舆情的能力，建立快速反应和应急处置机制，及时、妥善处理各类舆情对公司股 价、公司商业信誉及正常生产经营活动造成的影响，切实保护投资者合法权益， 根据《深圳证券交易所股票上市规则》等相关法律法规、部门规章、规范性文件 和《公司章程》等有关规定，结合公司的实际情况，制定本制度。 第二条 本制度所称舆情包括： （一）报刊、杂志、电视、广播、网络等媒体对公司进行的负面、不实报道； （二）社会上存在的已经或将给公司造成不良影响的传言或信息； （三）可能或者已经影响社会公众投资者投资取向，造成股价异常波动的信 息； （四）其他涉及公司信息披露且可能对公司股票及其衍生品交易价格产生较 大影响的事件信息。 第三条 舆情信息的分类： （一）重大舆情：指传播范围较广，严重影响公司公众形象或正常经营活 动，使公司已经或可能遭受损失，已经或可能造成公司股票及其衍生品种交易 价格变动的负面舆情； （二）一般舆情：指除重大舆情之外的其他舆情。 哈尔滨三联药业股份有限公司 舆情管理制度 第一章 总 则 第二章 舆情管理的组织体系 ...

哈尔滨三联药业股份有限公司 2024 年度独立董事述职报告 作为哈尔滨三联药业股份有限公司（以下简称"公司"）独立董事，本人在 2024 年度严格按照《公司法》、《上市公司独立董事管理办法》、《深圳证券交易所 上市公司自律监管指引第 1 号——主板上市公司规范运作》等法律、法规以及 《公司章程》、《独立董事工作制度》的相关规定，恪尽职守、勤勉尽责地履行 自身职责，积极出席公司相关会议，及时了解公司生产经营情况，对重大事项发 表独立、客观的意见，切实维护公司及全体股东的合法权益。现将本人 2024 年 度履职情况报告如下： 一、基本情况 （一）工作履历、专业背景以及兼职情况 本人刘洪泉，1959 年生，中共党员，中国国籍，无境外永久居留权。毕业 于中欧国际工商学院，工商管理硕士。曾任华瑞制药有限公司董事、总经理兼党 委书记，先声药业集团有限公司首席执行官，无锡凯夫制药有限公司总经理，费 森尤斯卡比（中国）投资有限公司总裁，费森尤斯卡比华瑞制药有限公司董事长； 现任江苏中贸发无锡医药有限公司董事长，无锡凯夫制药有限公司董事，无锡凯 夫科技有限公司执行董事，亿帆医药股份有限公司独立董事。自 2022 年 3 月至 ...

哈尔滨三联药业股份有限公司 董事会对独立董事独立性自查情况的专项报告 经核查独立董事刘洪泉先生、王栋先生、曾国林先生的任职经历以及签署的 相关自查文件等内容，董事会认为上述人员未在公司担任除独立董事以外的任何 职务，也未在公司主要股东公司担任任何职务，与公司以及主要股东之间不存在 利害关系或其他可能妨碍其进行独立客观判断的关系。因此，公司独立董事符合 《上市公司独立董事管理办法》、《深圳证券交易所股票上市规则》、《深圳证券交 易所上市公司自律监管指引第 1 号——主板上市公司规范运作》中对独立董事独 立性的相关要求。 哈尔滨三联药业股份有限公司 董事会 2025 年 4 月 23 日 根据《上市公司独立董事管理办法》、《深圳证券交易所股票上市规则》、《深 圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等法律 法规的相关规定，哈尔滨三联药业股份有限公司(以下简称"公司")董事会就公 司在任独立董事刘洪泉先生、王栋先生、曾国林先生的独立性情况进行评估并出 具专项意见如下： ...

Financial Performance - The company's operating revenue for 2024 was CNY 1,132,476,522.09, a decrease of 4.58% compared to CNY 1,186,786,001.40 in 2023[16]. - The net profit attributable to shareholders for 2024 was CNY 58,675,175.44, down 20.35% from CNY 73,663,110.90 in 2023[16]. - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 73.85% to CNY 53,233,408.45 in 2024 from CNY 30,619,980.53 in 2023[16]. - The net cash flow from operating activities for 2024 was CNY 30,687,788.46, a decline of 14.02% from CNY 35,693,579.98 in 2023[16]. - The total assets at the end of 2024 were CNY 3,800,468,270.17, reflecting a growth of 10.38% from CNY 3,442,984,089.62 at the end of 2023[16]. - The net assets attributable to shareholders at the end of 2024 were CNY 2,160,120,383.68, a slight increase of 0.92% from CNY 2,140,492,171.94 at the end of 2023[16]. - The basic earnings per share for 2024 were CNY 0.19, down 20.83% from CNY 0.24 in 2023[16]. - The diluted earnings per share for 2024 were also CNY 0.19, reflecting the same percentage decrease as the basic earnings per share[16]. - The weighted average return on net assets for 2024 was 2.75%, down from 3.57% in 2023[16]. Revenue Breakdown - The company's total revenue for the four quarters was as follows: Q1: ¥246.82 million, Q2: ¥276.62 million, Q3: ¥315.08 million, Q4: ¥293.95 million, indicating a steady growth trend[20]. - The net profit attributable to shareholders for the four quarters was: Q1: ¥18.79 million, Q2: ¥7.48 million, Q3: ¥14.31 million, Q4: ¥18.09 million, showing fluctuations in profitability[20]. - The net cash flow from operating activities improved significantly in Q4, reaching ¥75.81 million, compared to negative cash flows in the first three quarters[20]. - The pharmaceutical sector generated ¥989,103,863.08, accounting for 87.34% of total revenue, with a year-on-year decline of 13.48%[61]. - The veterinary medicine sector saw a significant increase in revenue to ¥75,198,173.15, up 740.79% from ¥8,943,788.35 in the previous year[61]. Industry Trends - The pharmaceutical industry is experiencing robust growth driven by population aging, improved healthcare systems, and rising health demands, positioning it as a key sector for long-term investment[24]. - The government has implemented a series of reforms in 2024 aimed at enhancing the pharmaceutical sector, including drug innovation and price governance, which are expected to support industry growth[25]. - The national drug procurement policy has led to an average price reduction of over 50% for selected drugs, significantly impacting market dynamics and competition[26]. - The shift from sales-driven to cost-driven strategies in the generic drug market is reshaping the competitive landscape, with companies focusing on cost management and innovation[27]. - The potential market space for the pharmaceutical sector in China remains substantial, despite short-term growth pressures, indicating long-term investment opportunities[24]. Research and Development - The company has established a comprehensive R&D and production system for chemical drug formulations, focusing on innovation and sustainable development[32]. - The company has a diversified product portfolio covering key therapeutic areas, with several products ranking among the top in their respective segments[34]. - The company has implemented an integrated "active pharmaceutical ingredients - formulations" strategy, ensuring drug quality and supporting the growth of its API business[34]. - The company is actively developing new products in the animal health sector, which is a strategic focus since the establishment of Harbin Longjiang Animal Health Biotechnology Co., Ltd. in 2021[37]. - The company is committed to ensuring the accuracy of its financial data and market insights to support strategic decision-making[36]. Market Expansion and Strategy - The company is focusing on expanding its market presence through innovative product development and strategic partnerships in the pharmaceutical and animal health sectors[37]. - The company has 23 generic drug varieties that have passed or are deemed to have passed the quality and efficacy consistency evaluation, with 10 core products selected for national centralized procurement[41]. - The company has established a production base for anti-coccidial raw materials with a fermentation capacity of 360m³, which has passed GMP certification[38]. - The company is focusing on the health consumer goods market, with three main business branches: beauty, medical device dressings, and food products[39]. - The company is expanding its veterinary injection product line with new approvals, including Vitamin C and other formulations[76]. Financial Management - The total operating costs for 2024 amounted to CNY 552,570,153.79, a significant increase from CNY 476,380,098.59 in 2023[68]. - The proportion of raw materials in the pharmaceutical industry’s operating costs decreased from 73.53% in 2023 to 62.05% in 2024, reflecting improved cost management[68]. - Financial expenses increased by 194.18% to ¥3,745,135.24, mainly due to a rise in interest expenses during the reporting period[74]. - R&D expenses decreased by 6.73% to ¥105,215,197.93, with no significant changes reported[74]. - The company reported an investment income of ¥32,419,272.15, accounting for 54.02% of total profit, primarily from equity method investments[84]. Governance and Compliance - The company has established a robust internal audit system to monitor and evaluate internal management effectively[148]. - The company has a complete independent business system, including R&D, production, and sales, without reliance on controlling shareholders[150]. - The company has adhered to various environmental protection laws and standards, ensuring compliance in its daily operations[191]. - The company has obtained all necessary environmental permits, including the "Pollutant Discharge Permit," for its subsidiaries[192]. - The company has implemented continuous improvements and refinements to its internal control systems in accordance with relevant laws and regulations[188]. Environmental Responsibility - The company has a wastewater discharge standard that complies with GB8978-1996, with a total discharge of 18 tons per day[196]. - The company paid an environmental protection tax of 8,753.08 yuan for the taxable pollutants including sulfur dioxide, nitrogen oxides, and smoke dust in 2024[199]. - The company has developed an emergency response plan for environmental pollution incidents, registered with local environmental authorities[198]. - The company’s boiler emissions are treated using magnesium oxide and SNCR methods to meet national standards[195]. - The company has received multiple environmental approvals and permits, including a wastewater discharge permit valid until December 2025[193]. Employee Engagement and Development - The company has implemented a comprehensive training plan focusing on enhancing core competitiveness and employee capabilities through a structured training system[179]. - The total number of employees at the end of the reporting period is 2,522, with 1,758 in the parent company and 764 in major subsidiaries[176]. - The professional composition includes 1,203 production personnel, 206 sales personnel, 747 technical personnel, 42 financial personnel, and 324 administrative personnel[176]. - The educational background of employees shows 4 with a doctorate, 117 with a master's degree, 857 with a bachelor's degree, 489 with an associate degree, and 1,055 with education below an associate degree[177]. - The company has established a performance evaluation and remuneration incentive system for directors and senior management based on their job responsibilities and performance indicators[185].

Revenue and Profit - The company's revenue for Q1 2025 was ¥205,027,782.58, a decrease of 16.93% compared to ¥246,819,438.23 in the same period last year[5] - The net profit attributable to shareholders was a loss of ¥28,845,105.91, representing a decline of 253.52% from a profit of ¥18,789,452.77 in the previous year[5] - Total revenue decreased to ¥205,027,782.58 from ¥246,819,438.23, a decline of approximately 17%[18] - Net profit turned negative at -¥29,795,441.26 compared to a profit of ¥17,414,092.70 in the previous period, indicating a significant decline[18] - Operating profit also fell to -¥35,207,091.55 from ¥18,914,975.05, marking a substantial decrease[18] - The total comprehensive income amounted to -29,795,441.26, down from 17,414,092.70 in the previous period[19] Earnings Per Share - Basic and diluted earnings per share were both -¥0.09, down 250.00% from ¥0.06 in the previous year[5] - The basic and diluted earnings per share were both -0.09, compared to 0.06 in the previous period[19] Cash Flow - The net cash flow from operating activities improved significantly to ¥86,305,192.39, a 341.32% increase from a negative cash flow of ¥35,763,547.76 in the same period last year[5] - Cash inflows from operating activities totaled 309,894,685.22, while cash outflows were 223,589,492.83[21] - The net cash flow from investing activities was -59,333,626.64, compared to -95,557,908.40 in the previous period[21] - Cash inflows from financing activities were 548,188,657.04, with cash outflows of 458,481,029.99, resulting in a net cash flow of 89,707,627.05[21] - The ending cash and cash equivalents balance was 672,160,767.37, up from 615,495,077.20 in the previous period[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,727,905,773.09, a decrease of 1.91% from ¥3,800,468,270.17 at the end of the previous year[5] - Total liabilities decreased to ¥1,592,613,755.20 from ¥1,636,313,285.80, a reduction of approximately 3%[15] - Owner's equity decreased to ¥2,135,292,017.89 from ¥2,164,154,984.37, a decline of about 1.3%[15] Expenses - Sales expenses decreased by 34.67% to ¥52,760,862.47 compared to ¥80,759,821.86 in the same period last year, mainly due to the impact of drug procurement policies[8] - Financial expenses increased by 165.74% to ¥4,377,685.71 from -¥6,659,002.31 in the previous year, primarily due to a significant reduction in interest income[8] - Research and development expenses decreased to ¥18,780,039.34 from ¥24,691,842.55, a reduction of approximately 24%[18] Government Subsidies and Other Income - The company received government subsidies amounting to ¥3,996,544.70, which were included in the current period's profit and loss[6] - Received cash from other operating activities increased to ¥63,055,036.01, a 233.16% increase compared to the previous period, mainly due to significant government subsidies and interest income from long-term loans[10] - Cash received from investment recoveries was ¥30,000,000.00, marking a 100% increase due to the redemption of financial products[10] - Cash received from investment income was ¥9,059,178.08, a 100% increase, resulting from cash dividends received from an associate company[10] Shareholder Information - The total number of common shareholders at the end of the reporting period was 29,272, with the largest shareholder holding 39.10% of the shares[11] - The largest shareholder, Qin Jianfei, has pledged 36,000,000 shares, representing a significant portion of his holdings[11]

证券代码：002900 证券简称：哈三联 公告编号：2025-021 哈尔滨三联药业股份有限公司 关于 2025 年度向银行等金融机构申请综合授信额度及为全资子 公司提供担保的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 哈尔滨三联药业股份有限公司（以下简称"公司"）拟为 4 家全资子公司提供 总额不超过 2 亿元的担保，本次被担保对象中 4 家的资产负债率超过 70%，敬请 投资者充分关注担保风险。 一、申请授信额度及提供担保情况概述 根据公司 2025 年业务发展所需生产经营资金需求，为了更好的支持公司业 务拓展，公司及子公司 2025 年度计划向农业银行、中国银行、建设银行、工商 银行、浦发银行、民生银行、招商银行、华夏银行、兴业银行、中信银行、广发 银行、农商银行等银行及其他金融机构申请综合授信总额度不超过 18 亿元，授 信品种包括但不限于短期流动资金贷款、中长期贷款、银行承兑汇票、贸易融资、 保函、信用证、项目贷款、抵押贷款、质押贷款等。同时，公司拟为 4 家全资子 公司申请 2025 年度综合授信额度提供总金额不超过 2 亿元 ...

哈尔滨三联药业股份有限公司 2024 年度监事会工作报告 2024 年度，哈尔滨三联药业股份有限公司（以下简称"公司"）监事会严格按 照《公司法》、《证券法》、《深圳证券交易所股票上市规则》等法律、法规以 及《公司章程》、《监事会议事规则》的相关规定，本着恪尽职守、勤勉尽责的 工作态度，依法独立行使职权，及时了解公司财务状况及经营成果，列席公司董 事会及股东大会会议，对公司治理的规范性和有效性、公司重大决策及重要经营 活动审议和执行情况、公司董事及高级管理人员勤勉履职等方面进行有效的监督 和检查，促进公司规范运作。现将监事会本年度工作情况报告如下： 一、2024 年度监事会工作情况 2024 年，公司监事会共召开 5 次会议，审议通过 23 项议案，监事会成员均 亲自出席会议并表决，具体情况如下： | 序号 | 时间 | 会议名称 | 审议事项 | | --- | --- | --- | --- | | 1 | 2024/4/24 | 第四届监事会 第十一次会议 | 年年度报告全文及摘要的议案》 1、审议《关于 2023 | | | | | 2、审议《关于 2023 年度监事会工作报告的议案》 | | | | ...

2024 年度内部控制评价报告 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要 求（以下简称"企业内部控制规范体系"），结合哈尔滨三联药业股份有限公司（以 下简称"公司"）内部控制制度和评价办法，在内部控制日常监督和专项监督的基 础上，对公司 2024 年 12 月 31 日的内部控制有效性进行了评价。 一、重要声明 哈尔滨三联药业股份有限公司 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其 有效性，并如实披露内部控制评价报告是公司董事会的责任。监事会对董事会建 立和实施内部控制进行监督。经理层负责组织领导企业内部控制的日常运行。公 司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存在任何虚假 记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个 别及连带法律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及 相关信息真实完整，提高经营效率和效果，促进实现发展战略。由于内部控制存 在的固有局限性，故仅能为实现上述目标提供合理保证。此外，由于情况的变化 可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低，根据内 ...

哈尔滨三联药业股份有限公司 2024 年度证券投资专项说明 根据《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范 运作》及哈尔滨三联药业股份有限公司（以下简称"公司"）《证券投资管理制度》 等相关规定的要求，董事会对公司 2024 年度证券投资情况进行了认真核查，公 司在充分保障日常运营性资金需求、不影响正常生产经营并有效控制风险的前提 下，使用自有闲置资金用于证券投资，现将具体情况说明如下： 一、证券投资审议情况 1、经公司 2017 年 12 月 25 日召开的第二届董事会第九次会议、第二届监事 会第六次会议审议通过《关于制定<哈尔滨三联药业股份有限公司风险投资管理 制度>的议案》《关于使用自有闲置资金进行风险投资的议案》，并经 2018 年 1 月 12 日召开的 2018 年第一次临时股东大会审议通过，同意自股东大会审议通过 之日起 12 个月内使用最高额度不超过 1 亿元人民币自有资金进行风险投资，期 限内可循环使用，独立董事及安信证券股份有限公司出具了同意的核查意见。 2、经公司 2018 年 12 月 21 日召开的第二届董事会第十九次会议、第二届监 事会第十三次会议及 201 ...

证券代码：002900 证券简称：哈三联 公告编号：2025-020 哈尔滨三联药业股份有限公司 2025 年度董事、监事及高级管理人员薪酬方案 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 哈尔滨三联药业股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日分 别召开第四届董事会第二十一次会议、第四届监事会第十七次会议，审议通过了 《关于 2025 年度董事薪酬方案的议案》、《关于 2025 年度高级管理人员薪酬方案 的议案》、《关于 2025 年度监事薪酬方案的议案》，公司高级管理人员薪酬方案自 董事会审议通过后生效，公司董事及监事薪酬方案尚需提交公司 2024 年年度股 东大会审议。现将具体情况公告如下： 根据《公司章程》、公司《董事会薪酬与考核委员会实施细则》等相关制度， 结合公司经营规模等实际情况并参照行业薪酬水平，经董事会薪酬与考核委员会 提议，公司制定 2025 年度董事、监事、高级管理人员薪酬方案： 一、本方案适用对象：公司董事、监事、高级管理人员 三、薪酬标准 1、公司董事薪酬方案 1）非独立董事在公司担任管理职务者，按其担任实 ...